150 likes | 262 Views
The importance of public-sector research in R & D. Johanne Iversen and Unni Gopinathan. Outline. 1. The role of public-sector research institutions 2. Appropriate licensing mechanisms for managing the intellectual property from publicly-funded research 3. Conclusions for the CEWG to consider.
E N D
The importance of public-sector research in R & D Johanne Iversen and Unni Gopinathan
Outline 1. The role of public-sector research institutions 2. Appropriate licensing mechanisms for managing the intellectual property from publicly-funded research 3. Conclusions for the CEWG to consider
Total Public-sector % from public sector FDA-approved drugs 1541 143 9.3% Priority review 348 66 19% • Other findings from new-drug applications from the public sector • 46%received priority review compared to 20% from the private sector • Accounted for 13.6% of NMEs • Acccounted for 21.1% of NMEs which had priority review Stevens et al, NEJM 2011
Total R&D funding for tropical neglected diseases in 2007 Moran, M., J. Guzman, et al. (2009). PLoS Med 6(2): e30
Goals of academic research 1. Science for the benefit of all2. Management of innovation to meet global needs3. Reciprocal responsibility of science and society Manchester Manifesto, University of Manchester
Issues within current managment of innovation and IP 1. Current innovation models do not reflect global health needs 2. Who uses the research and for what purpose? 3. Restrictions in access to new science may lead to duplication and waste Manchester Manifesto, University of Manchester
Innovations originating from public-sector research will have a greater impact on global health if appropriate intellectual property mechanisms are adopted
Harnessing the role of public-sector research institutions • Models for precompetitive research and development platforms • Open Source
Academic research in relation to other proposals • Adding research capacity for product development partnerships • Removal of data exclusivity • Patent pools
Conclusions • The Consultative Expert Working Group should consider: • the increasing importance of public-sector research in drug development • exploring appropriate academic intellectual property mechanisms which may strengthen other relevant proposals • exploring partnership models that can increase incentives for R & D • exploring models for precompetitive platform building within public- sector research institutions
Final conclusion Most importantof all: Innovative models must aim to meet the global burden of disease